Fortress Biotech

162 articles with Fortress Biotech

• Fortress Biotech Ranked in Deloitte’s Technology Fast 500™ for the Second Year in a Row

  11/18/2020

  Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that it ranked number 135 in Deloitte’s 2020 Technology Fast 500™, an annual ranking of the fastest-growing North American companies in the technology, media, telecommunications, life sciences and ene

• Fortress Biotech Reports Third Quarter 2020 Financial Results and Recent Corporate Highlights

  11/9/2020

  Product revenue for the first nine months of 2020 increased 29 % year-over-year to $ 30.8 million R olling submission of the New Drug Application for CUTX-101 is expected to begin in the first quarter of 2021 and be completed by the end of the second quarter of 2021

• Fortress Biotech Announces Oral and Poster Data Presentations at the 62nd American Society of Hematology (ASH) Annual MeetingClinical data on CAEL-101 for AL amyloidosis and MB-106 CD20-targeted CAR T cell therapy to be presented

  11/4/2020

  Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that data from two of its clinical programs have been accepted for presentation at the 62nd American Society of Hematology (ASH) Annual Meeting, which is being held virtually from December 5 – 8, 2020

• Fortress Biotech’s Partner Company, Journey Medical Corporation, to be Featured in Webinar Hosted by ROTH Capital Partners

  10/19/2020

  Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that Scott Henry, Managing Director, Senior Research Analyst and Head of Pharmaceuticals Research at ROTH Capital Partners, will host a webinar with the management team of Journey Medical Corporation

• Fortress Biotech Announces Initiation of Phase 3 Studies of CAEL-101 in AL Amyloidosis

  9/14/2020

  Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), today announced that Caelum Biosciences, Inc. (“Caelum”), in collaboration with Alexion Pharmaceuticals, Inc. (“Alexion”), initiated the Cardiac Amyloid Reaching for Extended Survival (CARES) Phase 3 clinical program to evaluate CAEL-101,

• Fortress Biotech to Participate in Three September 2020 Virtual Investor Conferences

  9/10/2020

  Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in three virtual investor conferences in September 2020. The company will also host virtual one-on-o

• Fortress Biotech Announces Pricing of Series A Preferred Stock Offering - Aug 27, 2020

  8/27/2020

  Fortress Biotech, Inc., an innovative biopharmaceutical company, announced that it has priced an underwritten public offering of 666,666 shares of its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock at a price of $18.00 per share, with expected gross proceeds to Fortress of approximately $12 million.

• Fortress Biotech Announces Virtual Two-Day Corporate Access Summit Hosted by B. Riley FBR on Tuesday, August 18 and Wednesday, August 19, 2020

  8/12/2020

  Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced a two-day summit hosted by Mayank Mamtani, of B. Riley FBR, Inc., that will feature multiple programs from Fortress’ diversified pipeline. The events will be held virtually on Tuesday, August 18, and

• Fortress Biotech Announces Positive Opinion on Orphan Drug Designation Received from the European Medicines Agency for CUTX-101, Copper Histidinate, for the Treatment of Menkes Disease

  7/31/2020

  Rolling submission of New Drug Application to the FDA for CUTX-101 on track to begin in the fourth quarter of 2020

• Fortress Biotech Announces Publication of Study on Targeted Next Generation Sequencing for Newborn Screening of Menkes Disease in Molecular Genetics and Metabolism Reports

  7/29/2020

  Cyprium Therapeutics, a Fortress partner company, is developing CUTX-101 for Menkes disease A rolling submission of a New Drug Application to the FDA is expected to begin in the fourth quarter of 2020

• Fortress Biotech Added to Russell 3000® Index

  6/29/2020

  Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing high-potential marketed pharmaceutical products and development-stage pharmaceutical product candidates, today announced that the company has been added to the Russell 3000 ® index, effective after the U.S. market opens today, following R

• Fortress Biotech to Present at the Raymond James Human Health Innovation Conference

  6/15/2020

  Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing high-potential marketed pharmaceutical products and development-stage pharmaceutical product candidates, today announced that Lindsay Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a company overview and host one-on-one investor meetings at the Raymond James Human Health Innov

• Fortress Biotech to Host Virtual Annual Meeting of Stockholders

  6/2/2020

  Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company, today announced that it will host the Company’s 2020 Annual Meeting of Stockholders (“Annual Meeting”) virtually due to public health concerns resulting from the coronavirus (“COVID-19”) outbreak, and government-recommended and required limits on public gatherings. Holding the Annual Meeting online will also protect the health and safety of the Company’s stoc

• Fortress Biotech Announces Pricing of Series A Preferred Stock Offering - May 27, 2020

  5/27/2020

  Fortress Biotech, Inc., an innovative biopharmaceutical company, announced that it has priced an underwritten public offering of 555,556 shares of its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock at a price of $18.00 per share, with expected gross proceeds to Fortress of approximately $10 million.

• Fortress Biotech Reports Record First Quarter 2020 Financial Results and Recent Corporate Highlights

  5/11/2020

  Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2020.

• Fortress Biotech Announces Exclusive Worldwide License Agreement With Columbia University to Develop Novel Oligonucleotide Platform for the Treatment of Genetically Driven Cancers

  5/8/2020

  Oncogenuity, Inc., a Fortress partner company, enters into an agreement with Columbia University to develop a broad platform technology using oligonucleotides Initial target is KRAS-driven cancers, often considered “un-druggable” Platform being explored as a treatment for coronaviruses, including COVID-19 NEW YORK, May 08, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company, today announced that Oncogenuity, Inc. (“Oncog

• Fortress Biotech Reports Record Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Highlights

  3/16/2020

  Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company, today announced financial results

• Fortress Biotech Announces Closing of Series A Preferred Stock Offering and Full Exercise of Over-Allotment Option

  2/24/2020

  Fortress Biotech, Inc. (Common Stock: Nasdaq: FBIO) (Preferred Stock: Nasdaq: FBIOP) (“Fortress”), today announced that the underwriters of its recent public offering of its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock have exercised in full their option and purchased an additional 93,750 shares at the public offering price of $20.00 per share.

• Fortress Biotech Announces Pricing of Series A Preferred Stock Offering - Feb. 11, 2020

  2/12/2020

  Fortress Biotech, Inc. announced that it has priced an underwritten public offering of 625,000 shares of its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock at a price of $20 per share, with expected gross proceeds to Fortress of $12.5 million.

• Fortress Biotech Announces Rare Pediatric Disease Designation for CUTX-101 for the Treatment of Menkes Disease

  1/16/2020

  Cyprium Therapeutics, a Fortress partner company, on track to begin submitting rolling New Drug Application for CUTX-101 to the FDA in the second